We report a new mechanism of aberrant pre-mRNA splicing resulting in constitutive activation of a mis-spliced oncoprotein (KIT) leading to malignancy (gastrointestinal stromal tumor) in contrast to loss of function of misspliced proteins resulting in diverse human diseases in the literature. The mechanisms of three consecutive molecular events, deletion of noncoding and coding regions encompassing the 3 0 authentic splice site, creation of a novel intra-exonic pre-mRNA 3 0 splice acceptor site leading to in-frame loss of 27 nucleotides (nine amino acids; Lys550-Lys558), and the mechanism of constitutive activation of the mis-spliced KIT are elucidated. Loss of a peptide in a critical location unleashed the protein from autoinhibition (as evidenced by three-dimensional structural analysis), causing KIT to become constitutively activated and resulting in the GIST phenotype. We also demonstrated that only one of the following two exonic splicing enhancers is sufficient for inclusion of the KIT exon 11 in vivo: AACCCATGT (nucleotides 2-10 from the 5 0 end, which are recognized by SC35, SRp55, and SF2/ASF) or GGTTGTTGAGG (nucleotides 27-37 from the 5 0 end, which are recognized by SC35 and SRp55), suggestive of exonic enhancer redundancy.
Introduction
The splicing of nuclear pre-mRNA is a fundamental process for the expression of most metazoan genes. More than half of reported exonic mutations in human disease and cancers are due to mutation-related aberrant pre-mRNA splicing (Nelson and Green, 1990; Di Blasi et al., 2001; Goldstrohm et al., 2001; Hammes et al., 2001; Harland et al., 2001; Liu et al., 2001; Cartegni et al., 2002; Ladd, 2002; Pagani et al., 2002; Aznarez et al., 2003; Buratti et al., 2003; Colapietro et al., 2003; Gorlov et al., 2003; Namour et al., 2003; Roca et al., 2003) . Accurate pre-mRNA splicing requires the integration of information provided by many cis-acting elements, tissue-specific trans-acting factors, and complex stepwise assembling of a splicesome (Smith and Valcarcel, 2000; Goldstrohm et al., 2001; Wagner and Garcia-Blanco, 2001; Cartegni et al., 2002; Black, 2003; Jurica and Moore, 2003; Pagani and Baralle, 2004) to carry out pre-mRNA splicing. This multi-step process involves the initial defining of the 5 0 border of the first exon by the 5 0 cap and the cap-binding complex, which is followed by recognition of each intron-exon boundary, splicing enhancers or silencers for each exon definition, and transesterification reactions for the removal of the noncoding intron sequences and ligation of protein-coding exon sequences into mature mRNA before their export into cytoplasm and translation. Exons encode amino-acid sequence as well as regulatory cis-elements, exonic splicing enhancers (ESEs) and exonic silencing enhancers (ESSs) for exon definition. Mutations involving the boundary between intron and exon (anthentic splice site) or regulatory elements (pyrimidine tract, branch point, intron or exon enhancers or silencers) are the common causes of disruption of authentic splice sites. The mechansisms of aberrant premRNA splicing secondary to disruption of authentic splice site most commonly involve exon skipping rather than intron retention (Goldstrohm et al., 2001; Buratti et al., 2003) , to a much lesser extent, involve activation of cryptic intra-exonic 5 0 splice site (Nelson and Green, 1990; Roca et al., 2003) or cryptic intra-exonic 3 0 splice site (Aznarez et al., 2003; Namour et al., 2003) . In very rare occations, mutation(s) can create an additional splice site inside intron and result in aberrant inclusion of part of an intron as a cryptic exon (Harland et al., 2001; Pagani et al., 2002) .
We describe a new mechanism of aberrant pre-mRNA splicing that involves deletion of noncoding and coding regions encompassing the authentic pre-mRNA intron 3 0 splice acceptor site (3 0 splice site) with subsequent creation of a novel intra-exonic 3 0 splice site. This novel site is not a cryptic 3 0 splice site; instead, it is created by the deletion and rejoining of the partially truncated intron and exon.
There is ample evidence that mis-spliced pre-mRNAs translating into truncated and nonfunctional proteins are associated with specific diseases or cancers, for example: b-globin in b-thalassemia (Nelson and Green, 1990; Roca et al., 2003) , the transcobalamin gene in transcobalamine deficiency disease (Namour et al., 2003) , ATM in ataxia-telangiectasia (Pagani et al., 2002) , NF1 in neurofibromatosis (Colapietro et al., 2003) , BRCA1 in breast or ovarian cancer (Liu et al., 2001) , human mismatch-repair genes hMSH2 and hMLH1 in human nonpolyposis colon cancer (Gorlov et al., 2003) , LAMA2 in muscular dystrophy (Di Blasi et al., 2001) , Wt1 in Frasier syndrome (Hammes et al., 2001; Ladd, 2002) , CFTR in cystic fibrosis, (Aznarez et al., 2003; Pagani and Baralle, 2004) and KIT in human piebaldism (congenital depigmentation in patches of skin and hair) (Syrris et al., 2002) . This is the first report of aberrant pre-mRNA splicing resulting in constitutive activation of a mis-spliced oncoprotein leading to human malignancy. This was discovered in two gastrointestinal stromal tumors (GISTs) showing in-frame loss of 27 nucleotides in exon 11 of KIT (nine amino acids; Lys550-Lys558). Deletion of these nine amino acids in a critical location in this mis-spliced KIT unleashed the protein from autoinhibition. At the same time, independently, Corless et al. (2004) reported KIT gene deletion at the intron 10-exon 11 boundary in 19 GISTs, four of them were further analysed by cDNA sequencing and these four GISTs showed the same deletion of codon 550-558 as reported here.
KIT is mapped to human chromosome 4q12. KIT is a member of the type III receptor tyrosine kinase family and is characterized by five immunoglobulin-like domains, a single transmembrane helix, an autoinhibitory juxtamembrane cytoplasmic domain and a cytoplasmic split kinase domain. A kinase insert divides the kinase domain into an ATP-binding region and a phosphotransferase region. Upon stem cell factor ligand binding, KIT forms a homodimer, autophosphorylates tyrosine residues and induces diverse signal transduction cascades. Autophosphorylated tyrosine 568 (pY568) serves as docking site for adapter protein APS, Csk-homologous kinase CHK, protein tyrosine phosphatase SHP-2 and Src family kinases; pY570 bind to tyrosine phosphatase SHP-1 and negatively modulates KIT; pY703 binds to Grb2; pY721 serves as the docking site for PI3-kinase; pY730 binds to phospholipase C-g and pY936 binds to adapter proteins APS, Grb2, and Grb7. Through these diverse signal transduction pathways and tissue-specific regulations, KIT plays important roles in hematopoiesis, melanogenesis, gametogenesis, and peristalsis. Gain-of-function KIT mutations have been implicated in mastocytosis, hematologic disorders, germ cell tumors, and GISTs (Hirota et al., 1998 Taniguchi et al., 1999; Isozaki et al., 2000; Allander et al., 2001; Sandberg and Bridge, 2002; Heinrich et al., 2003a, b; Kinoshita et al., 2003; Sommer et al., 2003; Koh et al., 2004) . Loss-of-function mutations in KIT result in human piebaldism (Syrris et al., 2002) .
GISTs originate from interstitial cells of Cajal, a network of innervated cells that coordinates peristalsis in the gastrointestinal system. Gain-of-function mutations of KIT have been demonstrated in 60-89% of GISTs (Hirota et al., 1998 Taniguchi et al., 1999; Isozaki et al., 2000; Allander et al., 2001; Sandberg and Bridge, 2002; Heinrich et al., 2003a, b; Kinoshita et al., 2003; Koh et al., 2004) while activation mutations of the platelet-derived growth factor receptor a (PDGFRA) have been demonstrated in 5-7% of GIST (Heinrich et al., 2003a, b; Hirota et al., 2003) ; and these mutations are mutually exclusive (Heinrich et al., 2003a, b; Hirota et al., 2003) . Another 4-7% of GISTs express both normal KIT and normal PDGFRA (Heinrich et al., 2003a, b; Hirota et al., 2003) . KIT exon 11 is the most frequent site of KIT mutation (up to 70%), and exon 9 mutations account for an additional 18% of cases (Heinrich et al., 2003a) ; mutations in exons 13 and 17 are rare . In a study using mice knocked in a KIT exon 11 mutation in which Lys558 was replaced by valine and found that the animals produced tumors indistinguishable from human GISTs (Sommer et al., 2003) . The KIT exon 11 mutation is most commonly clustered in the juxtamembrane cytoplasmic region, which results in pathologic release of KIT from autoinhibition and its constitutive activation (Ma et al., 1999; Chan et al., 2003; Mol et al., 2004) . A germine activation mutation, Lys642Glu, in KIT resulted in familial GIST (Isozaki et al., 2000) due to disruption of C-helix (codon 626-643), which plays crucial regulatory roles in KIT autoinhibition and lignad-induced activation (Ma et al., 1999; Chan et al., 2003; Mol et al., 2004) . These results indicate that constitutive KIT signaling is both critical and sufficient for the development of GIST.
Alternative splicing, which is physiological without involvement of mutation, plays an important role in embryonic development and allows proteomic complexity from a limited number of genes during evolution (Crosier et al., 1993; Zhu et al., 1994; Smith and Valcarcel, 2000; Graveley, 2002; Modrek and Lee, 2002; Black, 2003) . Two alternative splicing sites in KIT were first reported in leukemia cells (Crosier et al., 1993; Zhu et al., 1994) , one of which occurs at the 3 0 end of exon 9 in the juxtamembrane extracytoplasmic region, and the other at the 5 0 end of exon 15 in the kinase insert domain. These two alternative splicing sites are different from the mutation-created novel intra-exonic 3 0 splice site reported here.
Results

Genomic DNA sequencing
We studied 37 GISTs and found 20 of them harbor exon 11 mutation. Interestingly, two GISTS (GIST #1 and GIST #2) demonstrated deletions encompassing the noncoding region in intron 10 and the coding region in exon 11, which abolished the authentic pre-mRNA 3 0 splice site. DNA from peripheral blood mononuclear cells (PBMCs) from patients #1 and #2 was used as a control. Control DNA from PBMCs of patients #2 and #1 (data not shown) shows wild-type sequences of exon 11 and intron 10 (Figure 1) . The genomic DNA sequence of KIT from GIST #1 showed a 30-bp deletion (25 bp from exon 11 and 5 bp from intron 10), including the loss of the wild-type intron 10-exon 11 boundary, and the genomic DNA sequence of KIT from GIST #2 showed the same deletion plus an additional 4 bp deletion from intron 10 ( Figure 1 ). With this deletion of sequences containing the 3 0 splice site (intron 10-exon 11 boundary), conventional wisdom predicts exon skipping or alternative splicing, which does not apply here because none has been described in exon 11 of KIT. The skipping of exon 11 would cause loss of 127 nucleotides or 42 amino acids encoded by exon 11, as well as alteration in the reading frame, which would result in loss of function of the KIT.
GIST immunohistochemical characteristics and phenotype
The clinical pictures of patients #1 and #2 were that of patients with aggressive GIST since both presented with primary GIST in the stomach and liver metastasis. The tumors revealed the histologic features of GIST showing epithelioid and spindle cells arranged in irregular fascicles within a fibrous stroma and strong immunohistochemical (IHC) expression of KIT (Figure 2a, b) . Analysis of frozen sections of normal human skin (Figure 2c , e) and GIST #2 (Figure 2d , f) showed the expression of KIT with an anti-pan KIT antibody, as well as expression of pY568/570 KIT using an antibody against KIT peptide-specific phosphorylated Tyr568 and Tyr570 (pY568/570 antibody, polyclonal antibody that recognize both Tyr568 and Tyr570), which are the primary sites of KIT autophosphorylation in vivo (Mol et al., 2004) . Keratinocytes of normal human skin was used as negative control and melanocytes of normal human skin was used as positive control (Figure 2c , e). These findings suggest that Tyr568/570 are constitutively autophosphorylated, thus causing constitutive activation of KIT in GIST #2 and GIST #1 (data not shown). The clinical presentation, phenotype, and the IHC results of the GIST #1 and #2 are not consistent with the prediction of exon 11 skipping based on the genomic DNA sequences.
Direct sequencing analysis of cDNA
To explore why the genomic DNA sequences did not predict the phenotype and IHC results for GIST #1 and #2, we extracted RNA from the cryopreserved tumors. RNA from PBMCs of patients #1 and #2 was used as a control. The cDNA sequencing data of GIST #2 showed two out-of-phase but equally transcribed RNA sequences, one from the wild-type allele of KIT and one from a mutated allele that showed a loss of 27 nucleotides in exon 11 (Figure 3) . GIST #1 showed the identical cDNA sequence and nucleotide loss (data not shown). The forward sequence demonstrated the same 27-nucleotide loss in exon 11 in both GISTs (data not shown). These results surprised us because the genomic DNA sequencing data of both GISTs showed only a 25-bp deletion in exon 11 plus additional deletions in intron 10; the two extra nucleotides lost in exon 11 revealed in the cDNA sequence are unaccounted for by the genomic DNA sequence alone. In addition, exon 11 skipping did not happen despite abolishment of the intron 10-exon 11 boundary (the authentic pre-mRNA 3 0 splice site).
Mutation-created novel intra-exonic pre-mRNA 3 0 splice site
We propose that the discrepancy in genomic DNA and cDNA sequencing data can only be explained by two sequential molecular events in GIST #1 and #2: an initial genomic mutation with a 25-bp deletion in exon 11, and the creation during pre-RNA splicing of a novel pre-mRNA 3 0 splice site inside exon 11 at a location two nucleotides downstream from the genomic DNA 3 0 deletion site (Figure 4 ).
Pre-mRNA splicing consensus elements
The pre-mRNA intron 5 0 splice donor site (5 0 splice site) includes a consensus sequence of 'NNkgur', where the arrow indicates the exon-intron junction, the underlined bold letters denote highly conserved residues, 'r' denotes a purine, and 'N' denotes any nucleotide. Throughout this report, all intron sequences are typed in lower case and all exon sequences are typed in upper case. The 5 0 splice site is followed, frequently hundreds to thousands of base pairs downstream, by the branch point sequence 'pnpuracu', where 'p' denotes a pyrimidine. The consensus element of the branch point sequence is degenerative except for the 'a', which is highly conserved (Smith and Valcarcel, 2000; Goldstrohm et al., 2001; Wagner and Garcia-Blanco, 2001; Cartegni et al., 2002; Pagani and Baralle, 2004) . Although frequently measured in hundreds of bases, the average distance between the conserved 'a' in the pre-mRNA branch point and the pyrimidine tract is an estimated 18-40 bases (Smith and Valcarcel, 2000; Goldstrohm et al., 2001; Wagner and Garcia-Blanco, 2001; Cartegni et al., 2002; Pagani and Baralle, 2004) . The 3 0 splice site exhibits a consensus of As evidenced by the cDNA chromatograms (Figure 3) , which demonstrated equally expressed wild-type transcripts and the mutation-created mis-spliced transcripts with a loss of 27 nucleotides, the splicesome binds to the A Figure 4 Diagram of the mutation-created novel intra-exonic pre-mRNA 3 0 splice site. Black type indicates the wild-type genomic DNA sequence. Genomic DNA and pre-mRNA sequences of intron 10 are represented by lower case letters, and those of exons are represented by upper case letters. The pre-mRNA consensus elements are the branch point (green), polypyrimidine tract (blue), authentic pre-mRNA 5 0 and 3 0 splice sites (gray and black, respectively), mutation-created novel pre-mRNA intron 3 0 splice acceptor site (pink). Mutations involving noncoding and coding regions in KIT resulted in abolishment of the authentic intron10 pre-mRNA 3 0 splic acceptor site (long upward black arrow) and creation of a novel pre-mRNA intron 3 0 splice acceptor site (pink arrow) inside exon 11 in both GIST #1 and GIST #2. The mutation in the coding region in exon 11 is identical (a 25-bp deletion) in both GISTs, but the mutation in the noncoding region in intron 10 is different (a 4-bp deletion in GIST #1 and a 9-bp deletion in GIST #2)
Mutation-created novel pre-mRNA splice site in KIT LL Chen et al mutation-created novel intra-exonic pre-mRNA 3 0 splice site efficiently and transcribes this splicing variant effectively. This novel splice site offers a unique opportunity to examine consensus elements in premRNA splicing.
One consensus element is at the 3 0 end of the premRNA intron 10 splice acceptor site. The nucleotide sequences for the authentic and the mutation-created intra-exonic 3 0 splice sites are 'cagkA' and 'cagkG', respectively (Figure 4) . The authentic splice site uses 'cagk' from the 3 0 end of intron 10, whereas in GIST #1 and GIST #2, the mutation-created splice sites use a 'c' upstream (within the authentic polypyrimidine tract) of the intron 10 and an 'ag' from exon 11. Although the exact nucleotides of the authentic and the splicing variant come from different locations, the sequence is identical: 'cagkR'. The purine changes from 'A' in the authentic 3 0 splice site to 'G' in the mutation-created intra-exonic 3 0 splice site. Another consensus element is the pre-mRNA polypyrimidine tract within intron 10. The polypyrimidine tract of wild-type KIT consists of a run of 17 pyrimidines preceding the 3 0 pre-mRNA splice site. In GIST #1 and GIST #2, the polypyrimidine tracts are shorter (15 and 11 pyrimidines, respectively) but still longer than the average of 8 pyrimidines (Goldstrohm et al., 2001) , indicating that the length of the polypyrimidine tract is rather flexible and that the splicesome can accommodate up to 6 pyrimidines fewer with comparable efficiency (Figure 4) . The distances between the conserved 'a' in the pre-mRNA branch point and the beginning of the polypyrimidine tract in wild-type KIT and the mis-spliced KIT of GIST #1 and GIST #2 remained 30 nucleotides, which is in keeping with the reported average of 18-40 nucleotides (Smith and Valcarcel, 2000; Goldstrohm et al., 2001; Wagner and Garcia-Blanco, 2001; Cartegni et al., 2002; Pagani and Baralle, 2004) .
KIT intron 10 is short (90 nucleotides) and contains only one potential branch point ('uaaugacu') ( Figure 4 ). This sequence contains the highly conserved 'a' and an unusual residue at the third nucleotide upstream from the highly conserved 'a': this residue is an 'a' instead of the commonly encountered 'p' as reported in the literature (Goldstrohm et al., 2001; Cartegni et al., 2002; Pagani and Baralle, 2004) . Our data provide further evidence of the degenerative nature of the branch point consensus sequence in this particular position.
ESEs of KIT exon 11
The coding region (exon) not only dictates the aminoacid sequence but also defines the ESEs and ESSs. The functional ESEs are usually located close to the 5 0 portion of an exon and the ESSs are usually located in the middle or close to the 3 0 half of an exon (Cartegni et al., 2002; Pagani and Baralle, 2004) . ESEs are cisacting elements required for exon inclusion and serve as binding sites for Ser/Arg proteins (SR proteins), a family of conserved splicing factors that participate in multiple steps of the splicing pathway (Cartegni et al., 2002 (Cartegni et al., , 2003 Pagani and Baralle, 2004) . The most important human SR proteins include SF2, ASF, SC35, SRp55, and SRp40, each of which recognizes defined RNA motifs. We used ESEfinder, a web-based resource (Cartegni et al., 2003) , to examine the ESEs of exon 11 of wild-type KIT. A total of 15 ESEs had scores above threshold ( Figure 5) ; which of these ESEs are functional is unknown. In GIST #1 and #2, the loss of 27 nucleotides in exon 11 translated into loss of codons 550-558. These 27 nucleotides encompassed two stretches (nucleotides 2-10 and nucleotides 16-24) of highly conserved and overlapping ESEs. The first stretch contains ESEs beginning at second, fourth, and sixth nucleotide from the 5 0 end of exon 11 (ESEs 2, 4, and 6) and exhibits nucleotide sequences predicted to bind SC35, SF2/ASF, and SRp55, respectively, and the second stretch contains ESEs 16, 18, and 19 and exhibits nucleotide sequences predicted to bind SC35, SRp40, and SF2/ASF respectively. ESEs 2, 4, 6, 16, 18, and 19 are highly qualified and fulfill the known criteria as functional ESEs, but apparently they are not essential in vivo as evidenced by the existence of GIST #1 and GIST #2. The splicesome either prefers other ESEs as the functional wild-type ESEs or is capable of switching to other ESEs in the absence of these two stretches of ESEs as in the cases of GIST #1 and GIST #2.
We examined what would happen in the absence of ESEs 27 and 33 (equivalent to deletion of nucleotides 27-36 or codon 559-561). A literature search of reported KIT exon 11 mutations and our own unpublished data on 20 GISTs, we found GISTs with deletions encompassing exon 11 nucleotides 28-36 (codon 559-561) in 2 reports (Taniguchi et al., 1999; Allander et al., 2001 ) and deletion encompassing exon 11 nucleotides 22-36 (codon 557-561) in one report (Taniguchi et al., 1999) and our unpublished data. These observations indicate that in the absence of ESEs 27 and 33, ESEs 2, 4, 6, 16, 18, and 19 are sufficient for splicesome recognition. We then went on to examine the next logic question of whether the overlapping stretch of ESEs 2, 4, and 6 alone is sufficient for splicesome recognition. We searched for KIT mutation/deletion encompassing nucleotides 16-36 (codon 555-561) in GISTs and found this exact deletion (Taniguchi et al., 1999) and another two more GISTs with deletions encompassing exon 11 nucleotides 16-42 (codon 555-563) (Sandberg and Bridge, 2002) and nucleotides 16-63 (codon 555-570), respectively (Sandberg and Bridge, 2002) . These observations indicate that in the absence of ESEs 16-33, ESEs 2-6 is sufficient for splicesome recognition. We also examined what would happen in the absence of all three stretches of ESEs 2-33 (nucleotides 2-36 or codon 551-561). We searched for deletion encompassing KIT exon 11 nucleotides 2-36 (codon 550-561) in GISTs, piebaldism, mastacytosis, germ cell tumor, or leukemia without success. This observation indicates one of the two possibilities, either such a mutation is yet to be discovered or nonexisting because nucleotides 2-36 region is essential to define exon 11 inclusion.
In conclusion, either one of the two overlapping stretch of ESEs, the first stretch ESEs, AACCCATGT (nucleotides 2-10 from 5 0 end, recognizable by SC35, SRp55, and SF2/ASF) or the third stretch ESEs, GGTTGTTGAGG (nucleotides 27-37 from 5 0 end, recognizable by SC35 and SRp55), which are very different and far apart, is sufficient for KIT exon 11 inclusion in vivo. These results also indicate that SC35 and SRp55 are sufficient for wild-type KIT exon 11 definition, other SR proteins may play auxiliary or dispensable roles. While point mutation in ESEs have been reported to result in exon skipping (Liu et al., 2001; Cartegni et al., 2002; Buratti et al., 2003) suggestive of unique and indispensable nature, however, out data indicated redundancy of ESEs in KIT exon 11 definition in GIST.
Structural analysis of the mis-spliced KIT of GIST #1 and GIST #2
The creation of a novel pre-mRNA splicing site explains the perversion of exon 11 skipping and the 27-nucleotide loss. How KIT is constitutively activated remains to be elucidated, however. The loss of 27 nucleotides is translated into an in-frame deletion of nine amino acids (Lys550-Lys558). Knowledge of the three-dimensional structure of wild-type KIT, the exact location of splicing defects in three-dimentional configuration, and how wild-type KIT is regulated and activated at the molecular level is crucial for understanding the functional impact of this 9-amino-acid loss in KIT.
The juxtamembrane cytoplasmic domain (Thr544 to Trp580) of KIT has a dual role functioning both as an unphosphorylated autoinhibitory domain of signal transduction and as a substrate for trans autophosphorylation of Tyr568 and Tyr570 upon stem cell factor ligand binding and dimerization (Ma et al., 1999; Chan et al., 2003; Mol et al., 2004) . The unphosphorylated juxamembrane cytoplasmic domain forms a hairpin loop and maintains KIT in an autoinhibited state by shifting the control helix (C-helix) and blocking the activation loop (A-loop) from attaining an active conformation (Figure 6a+ ). In addition, Tyr553 of the juxtamembrane cytoplasmic domain forms a critical hydrogen bond with the buried and conserved Asp810 of the AspPheGly810-812 (DFG) motif in the autoinhibited configuration (Mol et al., 2004) . In this autoinhibited state, the hydrogen-bounded Phe811 along with the insertion of Trp557 from the juxtamembrane domain physically block the binding of ATP and thereby prevent autophosphorylation of Tyr568. When KIT transitions from an autoinhibited state (Figure 6a ) to an activated state (Figure 6b ), the C-helix aids in the interaction between the DFG motif and ATP and undergoes a major conformational change.
Deleting amino acids Lys550-Lys558 (Figure 6a ), which are in close proximity to the control helix (Chelix), disrupts several key autoinhibitory interactions of Figure 5 Predicted ESEs using ESEfinder (Cartegni et al., 2003) . The ESE recognition sequences (binding motif) for four human SR proteins within the entire KIT exon 11 (127 nucleotides, codon 550-591) are shown in X-axis. The four human SR proteins are colorcoded and their thresholds are listed at the bottom. The binding motif scores of four human SR proteins are shown in Y-axis. The numeral adjacent to each vertical bar identifies the 5 0 nucleotide of that binding site. In GIST #1 and GIST #2, the first 27 nucleotides from the 5 0 end of exon 11 are lost (light green horizontal bar) and result in abolishment of two stretches (nucleotides 2-10 and nucleotides 16-24) of highly conserved and overlapping ESEs (ESEs 2, 4, 6 and ESEs 16, 18, 19) the juxtamembrane cytoplasmic region with the C-helix and A-loop. Consequently, the C-helix is free to approach the space between the kinase N-lobe and kinase C-lobe, and the A-loop is free to form an extended and active conformation (Figure 6b ). In addition, the deletion of Tyr553 prevents formation of a hydrogen bond with Asp810 of the DFG motif. With the conformation of an extended and active A-loop, the Phe811 of the DFG motif is no longer able to physically block the ATP-binding site, thereby allowing autophosphorylation of Tyr568, followed by autophosphorylation at other sites including Tyr570, Tyr703, Tyr721, Tyr730, and Tyr936, resulting in constitutive activation of KIT, and ultimately the development of GIST.
Discussion
Dominant-activating mutation of KIT is sufficient in development of malignant phenotype of GIST, at the same time, dominant-negative mutation of KIT results in piebaldism exhibiting congenital depigmentation in patches of skin and hair. Mis-spliced proteins usually suffer substantial structural changes that result in loss of function, for example, a nonsense mutation in KIT resulted in termination of KIT in exon 6 and another two examples of splice site nucleotide substitution impair splicing resulted in dysfunctional KIT and human piebaldism (Syrris et al., 2002) . Both phenotypes of GIST and piebaldism are easily recognizable clinically and many mutational sequencing data have been reported, thus making KIT gene an excellent model in understanding of tumorigenesis, signal transduction and pre-mRNA splicing.
The mutation-created intra-exonic splice site provides insights into pre-mRNA splicing consensus elements and helps in mapping the functional ESEs in vivo as demonstrated in this report. Overexpression of mRNA of various oncogenes contributes to tumorigenesis in many tumor types. Understanding the mechanism of pre-mRNA splicing can help design therapy targeting at pre-mRNA splicesome and selectively inhibiting overexpression of oncogene with hopes to reverse the malignant phenotype.
This new mechanism of aberrant pre-mRNA splicing (Figure 4) can occur within any intron-exon junction within any protein as long as the genomic deletion fulfill the following three criteria: (1) genomic deletion of exon portion does not abolish ESEs that are essential for the recognition of SR proteins, (2) deletion encompasses the authentic 3 0 splice site with the exon 3 0 deletion site ends right before a sequence of 'PAGR' or 'AGR' (as in our GIST #1 and #2 which use 'p' from intron) to fulfill the essential cis-element for splicesome recognition, (3) deletion in intron portion starts after or near the 3 0 end of polypyrimidine tract, such that the pyrimidine tract maintains full function for exon definition. If the exon portion of deletion ends with 'AGR', then the intron portion of deletion needs to start right after a 'p'. Judging from these criteria, this type of aberrant premRNA splicing should not be a very rare event; however, the true incidence is difficult to estimate because many such aberrant pre-mRNA splicing would result in silent consequences and unnoticed. We discovered this new mechanism because of the unusual outcome of constitutive activation of a mis-spliced oncoprotein KIT in 2 GISTs. We identified two such cases, GIST #1 and GIST #2, among 37 cryopreserved GISTs in our Tissue Bank within a single institution in a period of 5 years. Corless et al. (2004) reported that KIT gene deletion at the intron 10-exon 11 boundary accounted for 2.6% (19/722) of GISTs.
Our study underscores the importance of analysing all molecular events -including genomic DNA, cDNA, pre-mRNA splicing, and protein structure in tumor biology. The combination of mutation plus aberrant pre-mRNA splicing using the mutation-created Kinase C-lobe Figure 6 Ribbon diagrams of the location of the 9-amino-acid loss (Lys550-Lys558) and its effect on the physical structure of KIT based on published crystal structure (Mol et al., 2004) . (a) Autoinhibited KIT. (b) Activated KIT. Gold, C-helix; green, A-loop; blue, DFG motif; yellow, juxtamembrane cytoplasmic domain; pink, amino acids Lys550-Lys558; gray, Tyr553; dotted green line, hydrogen bond between Tyr553 and Asp810 of the DFG motif intra-exonic 3 0 splice site represents a novel and effective molecular mechanism in generation of proteomic diversity as well as development of human disease and cancer.
Materials and methods
Tumor specimen GIST#1 and #2 had surgeries at MD Anderson Cancer Center and GISTs were cryopreserved in Tissue Procurement and Banking Facility and obtained with consent on IRB-approved laboratory protocol LAB02-433.
Genomic DNA and cDNA sequence analysis of KIT DNA was isolated from PBMCs and cryopreserved GISTs by using a QIAamp DNA mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA was extracted from frozen PBMCs and cryopreserved GISTs using standard methods and using the RNeasy mini column according to the manufacturer's instructions (Qiagen). cDNA was prepared using two-step Taqman reverse transcription reagent (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. A primer specific for KIT RNA was used (KIT 2961R, 5 0 -TTCCTGGAGGGGT GACCCAAACACT-3 0 ). The cDNA was then subjected to polymerase chain reaction. Taking into consideration the alternative splicing sites (Crosier et al., 1993; Zhu et al., 1994) and the hot spots of KIT mutation, we designed primers to sequence the cDNA encompassing exons 9-21 and genomic DNA sequence of exons 9, 11, 13, 15, and 17 in PBMCs and GIST cells. Nucleotide sequences were analysed using a 3730X1 DNA analyser (Applied Biosystems) at the University of Texas MD Anderson Cancer Center nucleic acid core facility.
IHC analysis on paraffin and frozen sections
Primary polyclonal antibody against KIT (pan KIT antibody; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for IHC analysis on paraffin sections of GISTs to assess the expression of KIT. Polyclonal antibody against KIT peptidespecific phosphorylated Tyr568/570 (pY568/570 antibody, the same antibody recognizes both phosphorylated Tyr568 and phosphorylated Tyr570; Biosource International, Camarillo, CA, USA) was used for IHC on frozen sections to assess the phosphorylation status of Tyr568/570 and, thus, KIT activation. Paraffin blocks were sectioned into 4 mm slices and placed on poly-L-lysine-coated slides. The tissue sections were deparaffinized in xylene, rehydrated with alcohol in graded steps, and transferred to phosphate-buffered saline. The slides were then blocked with 3% normal goat serum for 1 h and incubated in the primary antibody (1 : 100) for 3 h. The human normal skin and GISTs were oriented and embedded in OCT media and cryosectioned into 6 mm sections. Slides were fixed in cold acetone for 1 minute and rehydrated in PBS. They were blocked in 3% H 2 O 2 in PBS, followed by 3% normal goat serum. The slides were then incubated overnight at 41C with pY568/570 antibody (1 : 100). We used standard procedures using biotinylated secondary antibody followed by streptavidin-horseradish peroxidase, development with a DAB kit (Zymed Laboratories, Santa Cruz, CA, USA), and counterstaining with 10% hematoxylin. et al. (2004) reported the crystal structural of KIT. We obtained the structure coordinates for autoinhibited (1T45) and activated (1PKG) KIT from the Protein Data Bank and used Swiss-PdbViewer (Guex and Peitsch, 1997) to visualize the conformations.
Structural analysis of KIT
Mol
